Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue MMX lesion staining efficacy with split-dose bowel preparation for colonoscopy
2017-003505-17Phase 2Completed
- Sponsor
- Cosmo Pharmaceuticals
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lumeblue (2 arms), sponsored by Cosmo Pharmaceuticals. Primary endpoint: Colonic lesion staining and flagging efficacy. Started Oct 2021; status: completed.
02
Drugs
lumeblue
Beyond the preview
Go deeper on 2017-003505-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003505-17.